Dr. Jonathan Amatruda, MD

Dr. Amatruda practices at Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA.

Dr. Amatruda's NPI, 1912387713, was assigned on June 5, 2015. Dr. Amatruda graduated from University of Connecticut School of Medicine in 2015. Dr. Amatruda holds Maine license MD28202.

Dr. Amatruda's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center, at 1001 Potrero Avenue, San Francisco, CA 94110 in San Francisco County. The practice phone is (415) 206-8000.

Dr. Amatruda's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA. Dr. Amatruda is also affiliated with MaineHealth Maine Medical Center. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Amatruda to 2 more hospitals, 4 medical groups, 1 dialysis center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amatruda practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Amatruda's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Amatruda's licenses on file in 2 states: Maine and California.

CMS data shows 623 Medicare services from Dr. Amatruda across 7 procedure codes in 2024, for 192 Medicare patients. Medicare paid $116,806 for them.

CMS counts 192 Medicare patients who saw Dr. Amatruda in 2024. The largest group is 65 to 74, with 70 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 67% are also on Medicaid. Their average risk score is 7.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amatruda's median patient age at 72, with 43% women.

In 2024, Dr. Amatruda wrote 365 Medicare Part D claims for 69 patients. 84% of them were for generic drugs. CMS names the drug for 242 of them, across 9 drugs with 11 or more claims each, at $57,965 in total drug cost. In 2023, CMS named 198 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Amatruda for performance year 2024, reported through an alternative payment model (APM). Dr. Amatruda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Amatruda, published from 2012 to 2024. 2022 was the busiest year, with 3. The most frequent topics are Acute Kidney Injury and Sodium. Dr. Amatruda has published most often in Kidney Med. Dr. Amatruda's most frequent co-authors are Michael George Shlipak, MD, Michelle Mae Estrella, MD and Mary Cushman, MD.

Dr. Amatruda graduated from University of Connecticut School of Medicine in 2015.